Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07217171 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
A Phase 1 study of Bladder Cancer and Esophageal Squamous Cell Carcinoma, sponsored by EvolveImmune United.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 160
- Enrollment target
- 8
- Study locations
NCT07217171: Recruiting Phase 1 study of Bladder Cancer and Esophageal Squamous Cell Carcinoma, sponsored by EvolveImmune United.
NCT07217171 is a Phase 1 study of Bladder Cancer and Esophageal Squamous Cell Carcinoma that is actively recruiting participants, run by EvolveImmune United. The registered enrollment target is 160 participants, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (99% lower). The trial reports 8 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07217171, a Phase 1 study of Bladder Cancer and Esophageal Squamous Cell Carcinoma, is actively recruiting participants, sponsored by EvolveImmune United.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 160 participants
- Enrollment target
- 8
- Study locations
Study Summary
The goal of this study is to evaluate the safety and effectiveness of EVOLVE104 in participants with advanced urothelial and squamous cell carcinomas who have previously taken standard treatment options, have declined or have been ineligible for treatment with these medications. Participants with advanced or metastatic cancer who meet all eligibility criteria may be eligible to participate in the study.
Primary Outcome
TEAEs will be assessed during routine study visits and compared to Baseline to continuously evaluate safety and tolerability
Conditions Studied
Interventions
- DRUG EVOLVE104
Study Locations (8)
California
- USC/Norris Comprehensive Cancer Center - Los Angeles
Connecticut
- Yale University Cancer Center - New Haven
Georgia
- The Winship Cancer Institute Emory University - Atlanta
Michigan
- START Midwest - Grand Rapids
New York
- Memorial Sloan Kettering Cancer Center - New York
Pennsylvania
- Thomas Jefferson University, Sidney Kimmel Cancer Center - Philadelphia
Tennessee
- SCRI - Nashville
Virginia
- Virginia Cancer Specialists - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-11-13 |
| Est. Completion | 2031-01-29 |
| Phase | Phase 1 |
What NCT07217171 shows while recruiting
NCT07217171 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (99% lower).
The record links to 10 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which EVOLVE104 is the first listed.
NCT07217171 lists 8 locations in 8 states (California, Connecticut, Georgia).
Frequently Asked Questions
What is clinical trial NCT07217171 about?
NCT07217171 is a clinical study titled "A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas". The goal of this study is to evaluate the safety and effectiveness of EVOLVE104 in participants with advanced urothelial and squamous cell carcinomas who have previously taken standard treatment options, have declined or have been ineligible for treatment with these medications. Participants with ad...
What is the current status of trial NCT07217171?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 160 participants. The study started on 2025-11-13. Estimated completion is 2031-01-29.
What conditions does trial NCT07217171 study?
This clinical trial studies the following conditions: Bladder Cancer, Esophageal Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Cutaneous Squamous Cell Cancer.
What interventions are being tested in trial NCT07217171?
The interventions under investigation include: EVOLVE104 (DRUG).
Who is sponsoring clinical trial NCT07217171?
This trial is sponsored by EvolveImmune United, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07217171 being conducted?
This trial has 8 study locations across California, Connecticut, Georgia, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07217171's enrollment target sits among peer trials
160 66th of 175 higher than 110 of 175 other Bladder Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Sacituzumab Govitecan Plus EV in Metastatic UC
RECRUITING · Phase 1
-
Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI